Quarterly report pursuant to Section 13 or 15(d)

Note 2 - Selected Balance Sheet Data (Details Textual)

v3.8.0.1
Note 2 - Selected Balance Sheet Data (Details Textual)
$ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2018
USD ($)
Jun. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Mar. 31, 2018
USD ($)
Mar. 31, 2017
USD ($)
Available-for-sale Securities, Total $ 89,800 $ 66,100   $ 89,800  
Available-for-sale Securities, Gross Realized Gain (Loss), Total       23,700  
Payments to Acquire Available-for-sale Securities, Total       3,061 $ 1,625
Number of Reporting Units   3      
Goodwill, Impairment Loss       0  
Other Assets, Noncurrent, Total 27,064 $ 44,002   27,064  
Asset Impairment Charges, Total 16,246   16,226
Cost Method Investments $ 24,181 40,385   $ 24,181  
Astute Medical, Inc. [Member]          
Percentage of Ownership Interests 16.40%     16.40%  
Asset Impairment Charges, Total $ 16,200        
Cost Method Investments 23,800     $ 23,800  
Advanced Cell Diagnostics (ACD) [Member] | Available-for-sale Securities [Member]          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities 2,100     2,100  
ChemoCentryx, Inc (CCXI) [Member]          
Available-for-sale Securities, Total 86,600 59,600   86,600  
Available-for-sale Securities, Gross Realized Gain (Loss), Total       27,000  
Available-for-sale Equity Securities, Amortized Cost Basis, Total $ 29,500 $ 29,500   29,500  
Certificates Of Deposit [Member] | CHINA          
Payments to Acquire Available-for-sale Securities, Total       $ 1,400